Latest & greatest articles for digoxin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on digoxin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on digoxin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for digoxin

21. Digoxin for preventing or treating neonatal respiratory distress syndrome.

Digoxin for preventing or treating neonatal respiratory distress syndrome. BACKGROUND: This section is under preparation and will be included in the next issue. OBJECTIVES: To assess the effect of digoxin on clinical outcome in infants at risk of, or with, respiratory distress syndrome (RDS). SEARCH STRATEGY: Searches were made of the Oxford Database of Perinatal Trials, Medline (MeSH terms: digoxin; limits: age groups, newborn infants; publication type, clinical trial), previous reviews (...) including cross references, abstracts, conference and symposia proceedings, expert informants, and journal handsearching in the English language. SELECTION CRITERIA: Randomized controlled trials of digoxin in either the prevention or treatment of respiratory distress syndrome are included in this overview. DATA COLLECTION AND ANALYSIS: Data regarding clinical outcomes were excerpted from the trial reports by the reviewer. Data were analyzed according to the standards of the Cochrane Neonatal Review

Cochrane2000

22. Safety concerns about digoxin after acute myocardial infarction.

Safety concerns about digoxin after acute myocardial infarction. 10437870 1999 08 12 1999 08 12 2015 06 16 0140-6736 354 9176 1999 Jul 31 Lancet (London, England) Lancet Safety concerns about digoxin after acute myocardial infarction. 391-2 We examined clinical outcomes associated with non-randomised digoxin therapy in a postmyocardial infarction population with clinical heart failure (AIRE study). Our results raise concern about the safety of digoxin in this population. Spargias K S KS Hall (...) A S AS Ball S G SG eng Clinical Trial Comparative Study Letter Randomized Controlled Trial England Lancet 2985213R 0140-6736 0 Cardiotonic Agents 73K4184T59 Digoxin AIM IM Adult Cardiotonic Agents adverse effects therapeutic use Digoxin adverse effects therapeutic use Female Follow-Up Studies Heart Failure drug therapy mortality Humans Male Middle Aged Myocardial Infarction drug therapy mortality Product Surveillance, Postmarketing Tachycardia, Ventricular chemically induced mortality Treatment

Lancet1999

23. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group.

The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. 9036306 1997 02 25 1997 02 25 2013 11 21 0028-4793 336 8 1997 Feb 20 The New England journal of medicine N. Engl. J. Med. The effect of digoxin on mortality and morbidity in patients with heart failure. 525-33 The role of cardiac glycosides in treating patients with chronic heart failure and normal sinus rhythm remains controversial. We studied the effect of digoxin on mortality (...) and hospitalization in a randomized, double-blind clinical trial. In the main trial, patients with a left ventricular ejection fraction of 0.45 or less were randomly assigned to digoxin (3397 patients) or placebo (3403 patients) in addition to diuretics and angiotensin-converting-enzyme inhibitors (median dose of digoxin, 0.25 mg per day; average follow-up, 37 months). In an ancillary trial of patients with ejection fractions greater than 0.45, 492 patients were randomly assigned to digoxin and 496 to placebo

NEJM1997

24. Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure

Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure Ward R E, Gheorghiade M, Young J B, Uretsky B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Digoxin therapy in adult patients with stable congestive heart failure. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Adult patients with stable congestive heart failure. Setting Secondary care. The economic study was carried out in the USA Dates to which data

NHS Economic Evaluation Database.1995

25. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study.

Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. 8505940 1993 07 08 1993 07 08 2013 11 21 0028-4793 329 1 1993 Jul 01 The New England journal of medicine N. Engl. J. Med. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. 1-7 Although digoxin is effective in the treatment of patients with chronic heart failure who are receiving (...) diuretic agents, it is not clear whether the drug has a role when patients are receiving angiotensin-converting-enzyme inhibitors, as is often the case in current practice. We studied 178 patients with New York Heart Association class II or III heart failure and left ventricular ejection fractions of 35 percent or less in normal sinus rhythm who were clinically stable while receiving digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor (captopril or enalapril). The patients were randomly

NEJM1993

26. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure.

A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. 2646536 1989 04 12 1989 04 12 2013 11 21 0028-4793 320 11 1989 Mar 16 The New England journal of medicine N. Engl. J. Med. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. 677-83 We randomly assigned 230 patients in sinus rhythm with moderately severe heart failure to treatment with digoxin, milrinone, both (...) , or placebo. The effects of each were compared during a 12-week, double-blind trial. Treatment with milrinone or digoxin significantly increased treadmill exercise time as compared with placebo (by 82 and 64 seconds respectively; 95 percent confidence limits, 44 and 123, and 30 and 100). Both treatments reduced the frequency of decompensation from heart failure, from 47 percent with placebo to 34 percent with milrinone (P less than 0.05; 95 percent confidence limits, 22 and 46) and 15 percent with digoxin

NEJM1989

27. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group.

Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group. 2447297 1988 02 08 1988 02 08 2016 10 17 0098-7484 259 4 1988 Jan 22-29 JAMA JAMA Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group. 539-44 This multicenter, double-blind, placebo-controlled study compares the effects of captopril (...) treatment with those of digoxin treatment during maintenance diuretic therapy in patients with mild to moderate heart failure. Compared with placebo, captopril therapy resulted in significantly improved exercise time (mean increase, 82 s vs 35 s) and improved New York Heart Association class (41% vs 22%), but digoxin therapy did not. Digoxin treatment increased ejection fraction (4.4% increase) compared with captopril therapy (1.8% increase) and placebo (0.9% increase). The number of ventricular

JAMA1988

28. Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. The German and Austrian Xamoterol Study Group.

Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. The German and Austrian Xamoterol Study Group. 2893916 1988 04 07 1988 04 07 2015 06 16 0140-6736 1 8584 1988 Mar 05 Lancet (London, England) Lancet Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. The German and Austrian Xamoterol Study Group. 489-93 433 patients aged 29-80 with mild to moderate heart failure entered a multicentre double-blind randomised (...) between-patient comparison of xamoterol 200 mg twice daily, digoxin 0.125 mg twice daily, and placebo. Patients were assessed at baseline and after three months. Of 349 who completed the double-blind phase, 300 had valid exercise tests. Compared with placebo, xamoterol significantly increased exercise duration and work done on a bicycle ergometer and improved breathlessness and tiredness during daily life as assessed by visual analogue scale and by Likert scale. Digoxin showed no statistically

Lancet1988

29. Heart failure in outpatients: a randomized trial of digoxin versus placebo.

Heart failure in outpatients: a randomized trial of digoxin versus placebo. 7038483 1982 05 27 1982 05 27 2013 11 21 0028-4793 306 12 1982 Mar 25 The New England journal of medicine N. Engl. J. Med. Heart failure in outpatients: a randomized trial of digoxin versus placebo. 699-705 The view that digitalis clinically benefits patients with heart failure and sinus rhythm lacks support from a well-controlled study. Using a randomized, double-blind, crossover protocol, we compared the effects (...) of oral digoxin and placebo on the clinical courses of 25 outpatients without atrial fibrillation. According to a clinicoradiographic scoring system, the severity of heart failure was reduced by digoxin in 14 patients; in nine of these 14, improvement was confirmed by repeated trials (five patients) or right-heart catheterization (four patients). The other 11 patients had no detectable improvement from digoxin. Patients who responded to digoxin had more chronic and more severe heart failure, greater

NEJM1982

30. Effect of digoxin on right ventricular function in severe chronic airflow obstruction. A controlled clinical trial.

Effect of digoxin on right ventricular function in severe chronic airflow obstruction. A controlled clinical trial. Effect of digoxin on right ventri... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1981 ) Volume: 95 , Issue: 3 , Pages: 283-8 ISSN: 00034819 PubMed: Available from or Find this paper at: Abstract The effect of digoxin on the right and left ventricular ejection fractions (...) in 15 patients with pulmonary heart disease caused by severe chronic airflow obstruction was studied in a double-blind, randomized, placebo-controlled trial. All patients were ambulatory and had clinical features of right but not left ventricular dysfunction. Equilibrium radionuclide angiography showed reduced right ventricular ejection fraction in all patients and reduced left ventricular ejection fraction in four. After 8 weeks of digoxin treatment, the abnormal left ventricular ejection fractions

Annals of Internal Medicine1981

31. Trial of digoxin in mania.

Trial of digoxin in mania. 52007 1975 12 11 1975 12 11 2015 06 16 0140-6736 2 7936 1975 Oct 04 Lancet (London, England) Lancet Trial of digoxin in mania. 639-40 A suggestion that mania is associated with an increased membrane transport of sodium has been investigated in a double-blind trial of a specific Na-K A.T.P.ase inhibitor (digoxin) in twelve female inpatients with mania. Digoxin had no effect. Naylor G J GJ Worrall E P EP Watson Y Y Dick P P Stewart M M Peet M M eng Clinical Trial (...) Journal Article Randomized Controlled Trial England Lancet 2985213R 0140-6736 0 Placebos 73K4184T59 Digoxin 9NEZ333N27 Sodium AIM IM Biological Transport Bipolar Disorder drug therapy metabolism Clinical Trials as Topic Digoxin therapeutic use Female Humans Placebos Sodium metabolism 1975 10 4 1975 10 4 0 1 1975 10 4 0 0 ppublish 52007 S0140-6736(75)90119-1

Lancet1975